What Happens Before a Clinical Trial Begins? Understanding the Development of New Therapies for ALS
When the start of a clinical trial is announced, the news is often summarized in just a few words: “a new treatment enters Phase I.” Behind that moment, however, are years of research, regulatory evaluation, and a carefully designed sequence of steps intended to ensure that the process is both safe and scientifically sound. In […]
Innovation in Biotechnology: How New Therapies for ALS Are Developed
When we talk about innovation in healthcare, we often think of major breakthroughs or singular discoveries. In reality, in diseases such as amyotrophic lateral sclerosis (ALS), innovation is often quieter. It is the result of many small steps that gradually reshape how we understand the disease and how we can address it. For years, progress […]
Clinical Trials in Spain: A Strategic Opportunity to Accelerate Innovation in ALS
The development of new therapies for amyotrophic lateral sclerosis (ALS) does not rely solely on advances in biomedical research at the laboratory level. It also requires the ability to translate that knowledge into the clinical setting in an efficient, safe, and coordinated way. In this context, clinical trials in Spain have become a fundamental pillar […]
What does obtaining orphan drug designation in Europe mean and why is it key to innovation in ALS?
Orphan drug designation in Europe is a regulatory recognition granted by the EMA to treatments intended for rare diseases, such as ALS. This status provides key incentives—such as market exclusivity and scientific support—that reduce investment risk and accelerate therapeutic innovation, driving the development of new options for patients with urgent unmet medical needs.
The future of ALS research: why the coming years will be decisive
Amyotrophic lateral sclerosis (ALS) is one of the most complex and devastating neurodegenerative diseases of our time. For decades, biomedical research has progressed slowly, with limited therapeutic options and modest clinical impact. However, the landscape is changing. The coming years are shaping up to be a critical turning point for pharmaceutical research in ALS, driven […]